Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases. The Company is advancing a pipeline of three therapeutic product candidates, with a focus on its lead product candidate, PAS-004, a macrocyclic mitogen-activated protein kinase, or MEK inhibitor. PAS-004 is a small molecule allosteric inhibitor of MEK 1 and 2 (MEK 1/2) for potential use in the treatment of a range of RASopathies, including neurofibromatosis type 1 (NF1) and a number of oncology indications, among others. Its remaining two programs, PAS-001 and PAS-003, are in the earlier stages of development and are based on novel targets for the treatment of CNS disorders that it believes address limitations in the treatment paradigm of the indications it plans to address, which are amyotrophic lateral sclerosis (ALS) for its PAS-003 program, and schizophrenia for its PAS-001 program.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
30/10/26	USD 0.3702	+0.16%	100,161
29/10/26	USD 0.3696	-5.95%	329,816
28/10/26	USD 0.3930	-1.08%	596,824
27/10/26	USD 0.3973	-0.65%	649,428
26/10/26	USD 0.3999	-1.23%	628,873

Delayed Quote Nasdaq

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.3702USD

Average target price

3.000USD

Spread / Average Target

+710.37%

Consensus

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Pasithea Therapeutics Corp.

Company calendar

Market Closed - Nasdaq 07:00:00 31/10/26 am AEDT			5-day change	1st Jan Change
0.3702 ^USD	+0.16%		-8.57%	-71.30%

24/10	Pasithea Therapeutics Corp. Announces Positive PAS-004 Clinical Data From Phase 1 Advanced Cancer Study Presented At ESMO Congress 2026	CI
15/08	Pasithea Therapeutics Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

Market Cap	12.37M 11.08M 10.19M 9.23M 17.26M 1.17B 17.58M 122M 48.78M 618M 46.42M 45.44M 1.95B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	12.37M 11.08M 10.19M 9.23M 17.26M 1.17B 17.58M 122M 48.78M 618M 46.42M 45.44M 1.95B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	98.89%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq	KTTA	Delayed
CBOE	KTTA	Real-time

24/10	Pasithea Therapeutics Corp. Announces Positive PAS-004 Clinical Data From Phase 1 Advanced Cancer Study Presented At ESMO Congress 2026	CI
15/08	Pasithea Therapeutics Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
30/06	Pasithea Therapeutics Reports Positive Interim Phase 1 Advanced Cancer Study Data And Protocol Expansion	CI
30/06	Pasithea Therapeutics Says Interim Phase 1 Data for PAS-004 Show Durable Clinical Activity	MT
16/06	Pasithea Therapeutics Amends PAS-004 Trial to Add Higher Dose Levels, Extend Treatment	MT
16/06	Pasithea Therapeutics Amends Clinical Study Protocol for Phase 1/1B Nf1 Clinical Trial	CI
02/06	Pasithea Therapeutics Gets US FDA Orphan Drug Status for ALS Candidate	MT
16/05	Pasithea Therapeutics Corp. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04/05	Pasithea Therapeutics Corp. Appoints Kartik Krishnan as Chief Medical Officer, Effective May 1, 2026	CI
20/04	Pasithea Therapeutics Corp Announces Grant of Rare Pediatric Disease Designation by FDA to Pas-004 for Treatment of Neurofibromatosis Type 1	CI
01/04	Pasithea Therapeutics Corp Announces Grant of Fast Track Designation by Fda to Pas-004 for Treatment of Neurofibromatosis Type 1 Associated Plexiform Neurofibromas Causing Significant Morbidity	CI
31/03	Pasithea Therapeutics Corp. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03/03	Certain Pre-Funded warrants of Pasithea Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 3-MAR-2026.	CI

Pasithea Therapeutics Corp. Stock

Stocks

KTTA

US70261F2020

Biotechnology & Medical Research

Valuation: Pasithea Therapeutics Corp.

Chart: Pasithea Therapeutics Corp.

Latest news: Pasithea Therapeutics Corp.

Last Transcript: Pasithea Therapeutics Corp.

Analysts' recommendations: Pasithea Therapeutics Corp.

Press Releases: Pasithea Therapeutics Corp.

Quotes and Performance

Price Extremes

Managers and Directors: Pasithea Therapeutics Corp.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

08/12	HC Wainwright Initiates Coverage on Pasithea Therapeutics With Buy Rating, $3 Price Target	MT
04/04/23	EF Hutton Adjusts Price Target on Pasithea Therapeutics to $2 From $2.30, Maintains Buy Rating	MT

14/09	Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference	AQ
04/09	Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences	AQ
21/07	Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026	AQ
08/07	Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit	AQ
30/06	Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion	AQ

1 day	+0.16%
1 week	-8.57%
Current month	-24.91%
1 month	-24.91%
3 months	-16.62%
6 months	-46.71%
Current year	-71.30%

1 week	0.35	0.42
1 month	0.34	0.51
Current year	0.34	1.28
1 year	0.28	2.06
3 years	0.28	17.4
5 years	0.28	170
10 years	0.28	170

Manager	Title	Age	Since
Tiago Marques CEO	Chief Executive Officer	49	01/08/2020
Daniel Schneiderman DFI	Director of Finance/CFO	48	11/10/2022
Kartik Krishnan CTO	Chief Tech/Sci/R&D Officer	55	01/05/2026

Director	Title	Age	Since
Lawrence Steinman CHM	Chairman	78	-
Tiago Marques BRD	Director/Board Member	49	01/08/2020
Simon Dumesnil BRD	Director/Board Member	49	01/04/2021

Date	Insider	Type	Main position	Quantity	% Market Cap.
1/5/26	Alfred Novak	Free	Director	152,783	0.6126%
1/5/26	Emer Leahy	Free	Director	152,783	0.6126%
1/5/26	Kartik Krishnan	Free	Chief Technology Officer	1,129,323	4.5282%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PASITHEA THERAPEUTICS CORP.	+0.16%	-8.57%	-55.82%	-94.80%	12.37M
WUXI APPTEC CO., LTD.	-0.62%	-1.87%	+46.31%	+56.99%	63.77B
ARGENX SE	+0.35%	+3.20%	+14.92%	+84.55%	56.37B
LONZA GROUP AG	+0.53%	+1.96%	+15.37%	+106.81%	54.62B
IQVIA HOLDINGS INC.	-2.81%	-4.31%	+23.50%	+50.90%	44.06B
BEONE MEDICINES AG	-0.33%	-1.93%	+20.15%	+98.45%	42.11B
REVOLUTION MEDICINES, INC.	+0.55%	+2.31%	+224.97%	+942.56%	41B
GENMAB A/S	+3.27%	+47.96%	+112.67%	+96.48%	34.92B
CELLTRION, INC.	+1.22%	-1.44%	+14.89%	+47.15%	32.82B
INSMED INCORPORATED	+0.89%	+20.55%	-42.03%	+373.03%	24.7B
Average	+0.32%	+5.93%	+37.49%	+176.21%	39.44B
Weighted average by Cap.	+0.18%	+5.44%	+48.50%	+186.12%

	2026 *	2027 *
Net sales	-	-
Net income	-	-
Net Debt	-	-